ArticleCJC open2025
Equivocal vs Positive Technetium-99m-Pyrophosphate Scintigraphy for Transthyretin Amyloid Cardiomyopathy: Comparing Outcomes, Demographics, and Imaging.
Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodality imaging characterization of Perugini scintigraphic grades in transthyretin amyloid cardiomyopathy: a single-center experience.Journal of cardiovascular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transthyretin cardiac amyloidosis (ATTR-CM) is an underdiagnosed infiltrative cardiomyopathy. Diagnosis is based on Technetium-99m-pyrophosphate-bone-scintigraphy scans (Tc-99m-PYP) with grades 2 to 3 classified as positive. The clinical significance of grade 1 (classified equivocal by American Society of Nuclear Cardiology) is unclear. We aimed to describe the differences in clinical/imaging characteristics among those with equivocal vs positive Tc-99m-PYP and to describe outcomes of further investigations. Methods: We performed a retrospective study of patients who underwent Tc-99m-PYP at 2 institutions between January 2017 and November 2022. Baseline demographics, laboratory, and imaging data were collected. Results: A total of 502 Tc-99m-PYP were performed with single-photon emission computed tomography (SPECT) 3 hours post-tracer injection: 347 (69%) negative, 46 (9%) equivocal, and 109 (22%) positive. In the latter 2 groups, the median age was 78 (interquartile range [IQR]: 72-84) years, and 38 (25%) were female. Average follow-up was 19.7 ± 14.6 months. No patients with equivocal scans were diagnosed with ATTR-CM. Equivocal scans had lower intraventricular septal diameters (11 mm [IQR: 10-11] vs 15 mm [IQR: 12-17]), larger left ventricular end-diastolic dimension (50 mm [IQR: 44-56] vs 43 mm [IQR: 40-50]), and more negative global longitudinal strain (-18.7 [IQR: -22.2 to -18.7] vs -13.8 [IQR: -17.9 to -10.9] %). Only 12 (26%) patients with equivocal scans underwent further imaging or biopsy. Of 2 patients with monoclonal gammopathy, 1 had AL-amyloidosis. Conclusions: Our patients with equivocal grade 1 scans were not diagnosed with ATTR-CM. They exhibited distinct imaging compared to positive scans. Our findings suggest that ATTR-CM phenotype and equivocal scans may represent early ATTR-CM (ie, false negative) or false positives and should undergo further workup. Further research is needed to determine the significance of equivocal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.